TRx 0037

Drug Profile

TRx 0037

Alternative Names: TRx0037

Latest Information Update: 13 Nov 2012

Price : $50

At a glance

  • Originator TauRx Therapeutics
  • Class Antidementias
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 12 Nov 2012 Discontinued - Phase-I for Alzheimer's disease in Singapore (PO)
  • 12 Nov 2012 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 31 May 2010 TauRx Pharmaceuticals completes a phase I trial in Healthy adult and elderly volunteers [NCT01253499] in Singapore and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top